Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Current Assets (2016 - 2025)

Historic Current Assets for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $504.6 million.

  • Spyre Therapeutics' Current Assets rose 1983.59% to $504.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $504.6 million, marking a year-over-year increase of 1983.59%. This contributed to the annual value of $608.5 million for FY2024, which is 7816.23% up from last year.
  • Spyre Therapeutics' Current Assets amounted to $504.6 million in Q3 2025, which was up 1983.59% from $538.8 million recorded in Q2 2025.
  • Spyre Therapeutics' Current Assets' 5-year high stood at $608.5 million during Q4 2024, with a 5-year trough of $44.4 million in Q1 2023.
  • Moreover, its 5-year median value for Current Assets was $205.9 million (2023), whereas its average is $274.4 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Current Assets crashed by 5205.4% in 2022, and later surged by 99808.0% in 2024.
  • Spyre Therapeutics' Current Assets (Quarter) stood at $98.9 million in 2021, then tumbled by 37.04% to $62.3 million in 2022, then surged by 448.57% to $341.5 million in 2023, then skyrocketed by 78.16% to $608.5 million in 2024, then decreased by 17.07% to $504.6 million in 2025.
  • Its Current Assets was $504.6 million in Q3 2025, compared to $538.8 million in Q2 2025 and $569.8 million in Q1 2025.